Psoriasis Vulgaris
5 competing products in clinical development for Psoriasis Vulgaris.
Pipeline by Phase
Phase 21
Phase 31
Approved3
All Products (5)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Tildrakizumab | Sun Pharmaceutical | Approved | Completed | 43 |
| Brodalumab 210mg SC | Kyowa Kirin | Approved | Completed | 43 |
| KHK4827 140mg SC + KHK4827 210mg SC | Kyowa Kirin | Phase 3 | Completed | 40 |
| Tildrakizumab Prefilled Syringe | Sun Pharmaceutical | Approved | UNKNOWN | 39 |
| 0.03% E6201 + 0.1% E6201 + 0.2% E6201 + 0.005% E6201 + 0.01% E6201 + 0.05% E6201 + Calcipotriene | Eisai | Phase 2 | Completed | 35 |